1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,665 | 2,720 | 17:31 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.08. | BIOCYTOGEN-B (02315): ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 2 | HKEx | ||
| 10.07. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt Lizenzvereinbarung für Antikörper mit BeOne Medicines, um die Entwicklung innovativer Medikamente zu beschleunigen | 276 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), ein globales Biotechnologieunternehmen, das die Forschung und Entwicklung neuartiger Antikörper-basierter Medikamente mit... ► Artikel lesen | |
| 10.07. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development | 404 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies... ► Artikel lesen | |
| 18.06. | Biocytogen reagiert auf Patentansprüche von Harbour BioMed: RenNano ist eine unabhängig entwickelte Plattform mit eindeutigen Innovationen und voller Rechtsgültigkeit | 306 | Business Wire | Als Reaktion auf die jüngste Pressemitteilung von Harbour BioMed zu einer Verfahrensentwicklung in ihrem laufenden Rechtsstreit gibt Biocytogen folgende Erklärung ab:
Diese Pressemitteilung enthält... ► Artikel lesen | |
| 13.06. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE AND ESTABLISHMENT OF TRUST; AND PURCHASE OF SHARES FOR SHARE AWARD SCHEME | 1 | HKEx | ||
| 06.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen erhält japanisches Patent für RenMab Plattform und erweitert globales Patentportfolio für RenMice Plattform für vollständig humane Antikörper/TCR | 350 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) gab heute bekannt, dass die Schlüsseltechnologie seiner eigenständig entwickelten vollständig humanen Antikörper Mausplattform... ► Artikel lesen | |
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 06.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen und Nanjing Chia Tai Tianqing geben IND-Zulassung in China für gemeinsam entwickelten Anti-IGF-1R-Antikörper NTB003 (BCG009) bekannt | 324 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) und Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. ("NJCTTQ") melden, dass NTB003 (zuvor BCG009), ein gemeinsam entwickelter... ► Artikel lesen | |
| 05.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform | 258 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMabfully human antibody mouse platform has been granted... ► Artikel lesen | |
| 05.06. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT BIOCYTOGEN SECURES JAPAN PATENT FOR RENMAB PLATFORM, EXPANDS GLOBAL PATENT PORTFOLIO FOR RENMICE FULLY HUMAN ... | - | HKEx | ||
| 05.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009) | 375 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. ("NJCTTQ") announced that NTB003 (formerly BCG009), a co-developed... ► Artikel lesen | |
| 28.05. | BIOCYTOGEN-B (02315): POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING HELD ON MAY 28, 2025 | - | HKEx | ||
| 23.04. | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE USE AT THE 2024 ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BIOCYTOGEN-B (02315): NOTICE OF THE 2024 ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BIOCYTOGEN-B (02315): CIRCULAR FOR THE 2024 ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BIOCYTOGEN-B (02315): 2024 ANNUAL REPORT | 2 | HKEx | ||
| 26.03. | BIOCYTOGEN-B (02315): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 | - | HKEx | ||
| 14.03. | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | 4 | HKEx | ||
| 28.02. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT THE DEEPSEEK PLATFORM LOCALIZED DEPLOYMENT AND UPGRADE IN RESEARCH AND DEVELOPMENT STRATEGY OF ANTIBODY DRUGS ... | 1 | HKEx | ||
| 21.02. | BIOCYTOGEN-B (02315): ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE YEAR ENDED DECEMBER 31, 2024 | 1 | HKEx | ||
| 09.01. | Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment | 345 | Business Wire | Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to SOTIO Biotech, a... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,065 | -11,89 % | BRISANTE Meldung setzt Medigene Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
| BIOFRONTERA | 2,800 | +1,82 % | Biofrontera appoints George Jones as chief commercial officer | ||
| CLINUVEL | 6,780 | -0,59 % | CLINUVEL PHARMACEUTICALS LIMITED: Bioshares Biotech Summit presentation | ||
| EDITAS MEDICINE | 1,943 | +2,72 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,480 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
| ASEP MEDICAL | 6,021 | -100,00 % | Asep Medical validiert seinen Sepset(ER) Diagnosetest bei Patienten in der führenden wissenschaftlichen Fachzeitschrift Nature Communications. | 27. Mai 2025 / IRW-Press / Asep Medical Holdings Inc. ("Asep Medical" oder das "Unternehmen") (CSE: ASEP) (OTCQB: SEPSF) (FWB: JJ80) freut sich
bekanntzugeben, dass seine Tochtergesellschaft... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,990 | -0,75 % | A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts | ||
| CLEAN HARBORS | 205,20 | +0,10 % | Clean Harbors, Inc. Reports Fall In Q1 Profit, But Beats Estimates | WASHINGTON (dpa-AFX) - Clean Harbors, Inc. (CLH) revealed earnings for first quarter that decreased from last year but beat the Street estimates.The company's earnings totaled $58.68 million... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,900 | +0,42 % | Earnings Outlook For Spero Therapeutics | ||
| MESOBLAST | 1,240 | -0,80 % | Zelltherapie-Potenzial: Canaccord Genuity startet Coverage für Mesoblast mit Kaufempfehlung | ||
| CSTONE PHARMACEUTICALS | 0,770 | +0,65 % | CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress | Financial Performance: Strong Year-over-Year Improvement- Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.- ... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,410 | +2,17 % | Protalix Biotherapeutics Inc.: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer | CARMIEL, Israel, July 21, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 35,600 | +2,89 % | This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday | ||
| MERSANA THERAPEUTICS | 6,240 | +4,35 % | XFRA 0M40: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMERSANA THER.NEW... ► Artikel lesen | |
| PURPLE BIOTECH | 2,200 | 0,00 % | Purple Biotech Ltd.: Purple Biotech Reports Second Quarter 2025 Financial Results | Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG2A, and tumor-associated antigen arms... ► Artikel lesen |
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,83 % bei einem Aktienkurs von 2,675 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.